Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients

Pfizer

Status: Completed

Conditions: Arthritis, Rheumatoid

Treatments: Drug: Enbrel

Study type: Observational

Funder types: Industry

Identifiers

NCT04428424

B1801417

Details and patient eligibility

About

This study is to evaluate available local data in Iraqi patients with rheumatoid arthritis on Enbrel treatment with regards to the impact of Rheumatoid factor and Anti-cyclic citrullinated peptide using data from the Baghdad Teaching Hospital registry.

Enrollment: 1,493 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed RA patients.

  -≥18 years of age

• Did not receive previous another biological treatment

Exclusion criteria

• Had previous biological treatment
• Use of etanercept for less than 1 year

Trial design

1,493 participants in 1 patient group

Patients with rheumatoid arthritis

Description:

Iraqi patients with rheumatoid arthritis that received Enbrel as treatment for disease

Treatment:

Drug: Enbrel